OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacogenomics is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Identification of RNA Modification-Associated Single-Nucleotide Polymorphisms in Genomic Loci for Low-Density Lipoprotein Cholesterol Concentrations	45
Genetics and response to treatment with metformin for type 2 diabetes	28
Pharmacogenomics in Psychiatry – the Challenge of Cytochrome P450 Enzyme Phenoconversion and Solutions to Assist Precision Dosing	27
Evidence level for pharmacogenetic testing in antidepressant treatment: a systematic review	24
Pharmacogenomics for Prader-Willi syndrome: caregiver interest and planned utilization	19
miR-369-3p regulates the drug resistance of lung cancer cells by targeting PTPN12	15
Patient comprehension of preemptive pharmacogenomic results	14
How to implement pre-emptive pharmacogenetic testing in the acute hospital setting	13
Whole exome sequencing identifies rare variants involved in PPIX-metabolizing pathway in anti-TB drug-induced hepatitis	13
Assessing patient understanding of pharmacogenomic test results: a qualitative study	12
Pharmacogenomic variants affecting efficacy and safety of medicines acting on central nervous system among Sri Lankans	12
A systematic review of single nucleotide polymorphisms affecting allopurinol pharmacokinetics and serum uric acid level	11
Rapid point of care testing: the next frontier in pharmacogenomics	11
Assessing the Utility of Measurement Methods Applied in Economic Evaluations of Pharmacogenomics Applications	11
Contrasting ABCB1 Pharmacogenetics and Psychotropic Responses in Child and Adolescent Psychiatry: A case comparison	11
Acceptance of recommendations by a pharmacogenetics clinic	10
Severe systemic Adverse Reactions to Ophthalmic Timolol in a CYP2D6 Homozygous *4 Allele Carrier: A Case Report	10
Characterization of CYP2C19 Pharmacogenetic Variation in African Populations and Comparison with Other Global Populations	9
Selpercatinib for RET-positive advanced pancreatic cancer detected by liquid biopsy: a case-based insight	9
CYP2D6 genotyping in a Korean cohort: comparative analysis with Asian, Caucasian, and African populations	9
Integrated in a Systems Pharmacology Approach, Pharmacogenetics holds the Promise for Personalized Medicine in Neonates	9
Pharmacogenetic markers and macrolide safety in influenza patients: insights from a prospective study	9
Improving the Management of ALK-Rearranged Non-Small-Cell Lung Cancer Through a Mobile Application: A Physicians-Based Survey	8
Multiple Genetic Mutations Increase the Risk of Thrombosis Associated With Clopidogrel After Percutaneous Coronary Intervention	8
The cost–effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma	8

The Promise�of Digital Health in Healthcare Equity and Medication Adherence in the Disadvantaged Dementia Population	8
Workforce readiness for pharmacogenomics and key elements for sustainment within the Veterans Health Administration	8
Gene Polymorphisms Affect Postoperative Imatinib Plasma Levels and Edema in Adults With Gastrointestinal Stromal Tumor	8
Genetic polymorphisms and adverse reactions to antituberculosis therapy	8
UGT1A1 Genotype-Guided Dosing of Irinotecan: Time to Prioritize Patient Safety	8
A Survey of Physician Opinions in Russia in the Field of Pharmacogenetics of Cardiovascular Disease	8
Cost–Effectiveness of HLA-B58:01* Testing to Prevent Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis in Vietnam	8
Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics	7
Genetika+: Precision Medicine Solutions for Mental Health	7
EFfects of UGT1A , CYP2C9/19 and ABAT Polymorphisms on Plasma Concentration of Valproic Acid in Chinese Epi	7
Effects of CYP3A4 and CYP2C9 Genotype on Systemic Anastrozole and Fulvestrant Concentrations in SWOG S0226	7
Impact of genetic variants on fentanyl metabolism in major breast surgery patients: a candidate gene association study	7
A critical review of RAF inhibitors in BRAF-mutated glioma treatment	7
Association between CYP3A4 , CYP3A5 and ABCB1 Genotype and Tacrolimus Treatment Outcomes Among Allogeneic H	6
SLCO1B1 and ABCB1 Variants Synergistically Influence the Atorvastatin Treatment Response in South Indian Coronary Artery Disease Patients	6
TPMT and NUDT15 genotyping, TPMT enzyme activity and metabolite determination for thiopurines therapy: a reference laboratory experience	6
Pharmacogenomic implications of the differential distribution of CYP3A5 metabolic phenotypes among Latin American populations	6
DDX11-AS1 Modulates Dna Damage Repair to Enhance Paclitaxel Resistance of Lung Adenocarcinoma Cells	6
Predicting laboratory aspirin resistance in Chinese stroke patients using machine learning models by GP1BA polymorphism	6
The Festival of Genetics and Personalized Medicine	6
Carbamazepine Cutaneous Adverse Reactions and HLA Gene Variation in the Chinese Population: A Systematic Review and Meta-Analysis	6
Accuracy and technical characteristics of CYP2C19 point of care tests: a systematic review	6
Barriers and facilitators for implementing a pharmacogenetic passport: lessons learned from reusing sequencing data	6
Estimated clinical utility of multi-gene pharmacogenetic testing in a retrospective cohort of gynecology patients	5
Genetic risk factors for drug-induced long QT syndrome: findings from a large real-world case–control study	5
Exploring the Potential Benefits of Pharmacogenomics in Chronic Respiratory Diseases	5
Patient Satisfaction With Return of Pharmacogenomic Results Utilizing a Patient Portal Message	5
Knowledge and Attitudes of Incoming Pharmacy Students Toward Pharmacogenomics and Survey Reliability	5
Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversion	5
The Genetics of Drug-Induced Qt Prolongation: Evaluating the Evidence for Pharmacodynamic Variants	5
XDH Genotypes Through Gene–Gene Interactions with NUDT15 Affect Azathioprine-Induced Leukopenia in Chinese Patients	5
Pharmacogenomics in Pediatric Medicine and Drug Development	5
Donor-Derived Cell Free DNA as a Biomarker in Kidney Transplantation	5
Genetic polymorphisms of OPRM1 on the Efficacy and Safety of Anesthetic and Analgesic Agents: A Systematic Review	5
Correction	5
The Revolution of Pharmaco-Omics: Ready to Open new Avenues in Materializing Precision Medicine?	4
Pharmacogenomic curriculum in Australian medical schools: a content analysis study	4
Overview of the Year 2023 at Pharmacogenomics	4
DPYD Genotyping and Predicting Fluoropyrimidine Toxicity: Where do we Stand?	4
Single-Nucleotide Polymorphisms in ABC Drug Transporters Alter Expression and Circulating Tenofovir in Healthy South African Women Exposed to Pre-Exposure Prophylaxis	4
Congruence Rates for Pharmacogenomic Noninterruptive Alerts	4
The Importance of Phenoconversion when using the CYP2D6 Genotype in Clinical Practice	4
Healthcare Professionals’ Knowledge, Confidence and Perceptions of Pharmacogenomics in Primary Care and Pain Management	4
Variation in the ABC transporter genes and association with clinical outcomes in colorectal cancer: a brief review	4
Impact of ABCB1 gene polymorphism on clopidogrel plasma concentration and cardiovascular events in post-PCI patients	4
Relevance of NAT2 Genotype and Clinical Factors to Risk for Antituberculosis Drug-Induced Liver Injury	4
Influence of CYP3A5 , IL-10 Polymorphisms and Metabolism Rate on Tacrolimus Exposure in Renal Post-Transplant Recipients	4
CYP2C:TG haplotype in Ecuador and Nicaragua: insights into CYP2C19 genotype–phenotype correlation in context to Mestizo popula	4
Posttransplantation diabetes mellitus (PTDM): pharmacological aspects and genetic predispositions	4
Evaluation of Pentamidine Tolerability and Efficacy Between CYP2C19 Phenotypes	4

Pharmacogenetics of Calcineurin inhibitors in kidney transplant recipients: the African gap. A narrative review	4
Clinical Pharmacology and Pharmacogenomics for Implementation of Personalized Medicine	4
Genome-Wide Association Study of Liver Enzyme Elevation in an Extended Cohort of Rheumatoid Arthritis Patients Starting Low-Dose Methotrexate	4
Clinically actionable genetic variation in patients with or at high-risk of cardiovascular diseases from the Montreal Heart Institute	4
Liquid biopsy: an essential tool for metastatic breast cancer’s follow-up	4
Impact of CYP2C19 Gene Polymorphisms on Warfarin Dose Requirement: A Systematic Review and Meta-Analysis	4
Pharmacogenomics: A Tool to Improve Medication Safety and Efficacy in Patients with Cystic Fibrosis	4
The Frequency Of Rs2231142 in ABCG2 Among Native Hawaiian nd Pacific Islander Subgroups: Implications for Personalized Rosuvastatin Dosing	4
Association of CYP2C19 , CYP3A4 and ABCC2 Polymorphisms and Voriconazole Plasma Concentrations in Uygur Ped	4
Artificial intelligence, medications, pharmacogenomics, and ethics	4
Psychiatric Level 1A Evidence Pharmacogenomics in a Brazilian Admixed Cohort and Global Populations	4
Leveraging Clinical Decision Support to Reduce the Risk of Discordant Pharmacogenomics Results	4